We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How is NY Times (NYT) Poised Ahead of Q2 Earnings Release?
Read MoreHide Full Article
The New York Times Company (NYT - Free Report) is likely to register a decrease in the top line when it reports second-quarter 2020 numbers on Aug 5, before the market opens. The Zacks Consensus Estimate for revenues is pegged at $388.5 million, suggesting a decline of about 11% from the prior-year reported figure.
The company’s bottom line is also expected to fall year over year. The Zacks Consensus Estimate for earnings for the quarter under review has remained stable at 5 cents in the past 30 days. The figure indicates a sharp decline from 17 cents reported in the year-ago period.
Notably, this diversified media conglomerate has a trailing four-quarter earnings surprise of 13.1%, on average. In the last reported quarter, the company delivered an earnings surprise of 30.8%.
Factors to Note
The New York Times Company has been grappling with declining print readership and soft advertising revenues for quite some time now. Readers’ preference for accessing news online, mostly free, has made the print-advertising model increasingly redundant. Also, the ongoing pandemic has compelled industries across the board to curtail marketing expenditures.
Management on its last earnings call guided a decline of approximately 50-55% in total advertising revenues for the quarter to be reported primarily owing to the impact of the coronavirus. Additionally, the company had projected a slump of roughly 40-45% in digital advertising revenues.
Nonetheless, the company has been making concerted efforts to lower dependency on traditional advertising and focus on digitization. The company has been diversifying business, adding new revenue streams and streamlining operations to increase efficiencies. It has been gearing up to become not only an optimum destination for news and information but is also focusing on lifestyle products and services.
Moreover, with readers’ increasing preference for accessing news online, the company has been concentrating on online activities, as evident from its pay-and-read model. We note that management had earlier forecast an increase of mid-to-high-single digits in total subscription revenues and a jump of high-twenties in digital-only subscription revenues for the second quarter.
The New York Times Company Price, Consensus and EPS Surprise
Our proven model does not conclusively predict an earnings beat for The New York Times Company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
Although The New York Times Company carries a Zacks Rank #3, it has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat:
The ODP Corporation (ODP - Free Report) has an Earnings ESP of +2.44% and a Zacks Rank of #2.
Roku, Inc. (ROKU - Free Report) has an Earnings ESP of +34.74% and a Zacks Rank of #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
How is NY Times (NYT) Poised Ahead of Q2 Earnings Release?
The New York Times Company (NYT - Free Report) is likely to register a decrease in the top line when it reports second-quarter 2020 numbers on Aug 5, before the market opens. The Zacks Consensus Estimate for revenues is pegged at $388.5 million, suggesting a decline of about 11% from the prior-year reported figure.
The company’s bottom line is also expected to fall year over year. The Zacks Consensus Estimate for earnings for the quarter under review has remained stable at 5 cents in the past 30 days. The figure indicates a sharp decline from 17 cents reported in the year-ago period.
Notably, this diversified media conglomerate has a trailing four-quarter earnings surprise of 13.1%, on average. In the last reported quarter, the company delivered an earnings surprise of 30.8%.
Factors to Note
The New York Times Company has been grappling with declining print readership and soft advertising revenues for quite some time now. Readers’ preference for accessing news online, mostly free, has made the print-advertising model increasingly redundant. Also, the ongoing pandemic has compelled industries across the board to curtail marketing expenditures.
Management on its last earnings call guided a decline of approximately 50-55% in total advertising revenues for the quarter to be reported primarily owing to the impact of the coronavirus. Additionally, the company had projected a slump of roughly 40-45% in digital advertising revenues.
Nonetheless, the company has been making concerted efforts to lower dependency on traditional advertising and focus on digitization. The company has been diversifying business, adding new revenue streams and streamlining operations to increase efficiencies. It has been gearing up to become not only an optimum destination for news and information but is also focusing on lifestyle products and services.
Moreover, with readers’ increasing preference for accessing news online, the company has been concentrating on online activities, as evident from its pay-and-read model. We note that management had earlier forecast an increase of mid-to-high-single digits in total subscription revenues and a jump of high-twenties in digital-only subscription revenues for the second quarter.
The New York Times Company Price, Consensus and EPS Surprise
The New York Times Company price-consensus-eps-surprise-chart | The New York Times Company Quote
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for The New York Times Company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
Although The New York Times Company carries a Zacks Rank #3, it has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat:
Maxar Technologies has an Earnings ESP of +31.71% and a Zacks Rank of #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The ODP Corporation (ODP - Free Report) has an Earnings ESP of +2.44% and a Zacks Rank of #2.
Roku, Inc. (ROKU - Free Report) has an Earnings ESP of +34.74% and a Zacks Rank of #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>